Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Purpose

This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.

Conditions

  • Metastatic Melanoma
  • Recurrent Melanoma
  • Stage III Cutaneous Melanoma AJCC v7
  • Stage IIIA Cutaneous Melanoma AJCC v7
  • Stage IIIB Cutaneous Melanoma AJCC v7
  • Stage IIIC Cutaneous Melanoma AJCC v7
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Unresectable Cutaneous Melanoma

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Criteria


Inclusion Criteria:

- STEP 1

- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1

- Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab
or dabrafenib + trametinib on the developing human fetus are unknown

- All females of childbearing potential must have a blood test or urine study
within 2 weeks prior to registration to rule out pregnancy

- A female of childbearing potential is any woman, regardless of sexual orientation
or whether they have undergone tubal ligation, who meets the following criteria:
1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
at any time in the preceding 24 consecutive months)

- The effects of dabrafenib and trametinib or ipilimumab and nivolumab on the developing
human fetus are unknown; furthermore, dabrafenib has been reported to interfere with
the effect of hormone based oral contraceptives; for this reason and because other
therapeutic agents used in this trial are known to be teratogenic, women of
child-bearing potential and sexually active males must agree to use at least two other
accepted and effective methods of contraception and/or to abstain from sexual
intercourse for the duration of their participation in the study, and for at least 4
weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination
with trametinib; women of child-bearing potential must use at least two other accepted
and effective methods of contraception and/or to abstain from sexual intercourse for
at least 5 months after the last dose of nivolumab and/or ipilimumab and sexually
active males must use at least two other accepted and effective methods of
contraception and/or abstain from sexual intercourse for at least 7 months after the
last dose of nivolumab and/or ipilimumab; should a woman become pregnant or suspect
she is pregnant while she is participating in this study, she should inform her
treating physician immediately

- Patients must have unresectable stage III or stage IV disease

- Patients must have measurable disease; all sites of disease must be evaluated within 4
weeks prior to randomization

- Patients must have histological or cytological confirmation of melanoma that is
metastatic or unresectable and clearly progressive

- NOTE: Any patient with BRAF V600 mutant melanoma (whether cutaneous, acral or
mucosal primary) who meets the eligibility criteria is eligible for participation
in this trial; patients with uveal melanoma are not eligible for this trial

- Patients must have BRAF V600 mutation, identified by a Food and Drug Administration
(FDA)-approved test at a Clinical Laboratory Improvement Act (CLIA)-certified lab; if
test at CLIA-certified lab used a non-FDA approved method, information about the assay
must be provided (FDA approved tests for BRAF V600 mutations in melanoma include:
THxID BRAF Detection Kit and Cobas 4800 BRAF V600 Mutation Test, Foundation Medicine);
prompt information on tumor BRAF mutation status can also be obtained via Novartis
"knowNow" Program

- Patients may have had prior systemic therapy in the adjuvant setting; however this
adjuvant treatment must not have included a CTLA4 or PD1 pathway blocking antibody or
a BRAF/MEK inhibitor; also, patients may not have had any prior systemic treatment for
advanced (measurable metastatic) disease

- Patients must have discontinued chemotherapy, immunotherapy or other investigational
agents used in the adjuvant setting >= 4 weeks prior to entering the study and
recovered from adverse events due to those agents; mitomycin and nitrosoureas must
have been discontinued at least 6 weeks prior to entering the study; patients must
have discontinued radiation therapy >= 1 week prior to entering the study and
recovered from any adverse events associated with treatment; prior surgery must be >=
2 weeks from registration and patients must be fully recovered from post-surgical
complications

- Patients must not receive any other investigational agents while on study or within
four weeks prior to registration

- Patients are ineligible if they have any currently active central nervous system (CNS)
metastases; patients who have treated brain metastases (with either surgical resection
or stereotactic radiosurgery [SRS]) could be eligible; patients must not have taken
any steroids =< 10 days prior to randomization for the purpose of managing their brain
metastases; repeat imaging after SRS or surgical resection is not required so long as
baseline magnetic resonance imaging (MRI) is within 4 weeks of registration; patients
with multiple brain metastases treated with SRS (with [w] or without [w/o] whole-brain
radiotherapy [WBRT]), are not an exclusion; patients with definitive CNS metastases
treated with only WBRT are ineligible; patients with potential CNS metastases that are
too small for treatment with either SRS or surgery (e.g. 1-2 mm) and/or are of
uncertain etiology are potentially eligible, but need to be discussed with and
approved by the study principal investigator (PI)

- Patients must not have other current malignancies, other than basal cell skin cancer,
squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in
situ of the breast; patients with other malignancies are eligible if they have been
continuously disease-free for > 2 years prior to the time of registration

- White blood count >= 3,000/uL (obtained within 4 weeks prior to randomization)

- Absolute neutrophil count (ANC) >= 1,500/uL (obtained within 4 weeks prior to
randomization)

- Platelet count >= 100,000/uL (obtained within 4 weeks prior to randomization)

- Hemoglobin > 8 g/dL (obtained within 4 weeks prior to randomization)

- Serum creatinine =< 1.5 x upper limit of normal (ULN) or serum creatinine clearance
(CrCl) >= 40 ml/min (obtained within 4 weeks prior to randomization)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x
ULN for patients with documented liver metastases)

- Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement
and =< 7 x ULN for patients with known bone involvement) (obtained within 4 weeks
prior to randomization)

- Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those
with known Gilbert's syndrome (obtained within 4 weeks prior to randomization)

- Patients must not have any serious or unstable pre-existing medical conditions (aside
from malignancy exceptions specified above), including but not limited to, ongoing or
active infection requiring parenteral antibiotics on day 1, or psychiatric
illness/social situations that would limit compliance with study requirements,
interfere with subject's safety, or obtaining informed consent; therapeutic level
dosing of warfarin can be used with close monitoring of prothrombin time
(PT)/international normalized ratio (INR) by the site; exposure may be decreased due
to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted
based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may
be increased and thus close monitoring via PT/INR and warfarin dose adjustments must
be made as clinically appropriate; prophylactic low dose warfarin may be given to
maintain central catheter patency

- Patients must not have a history of or evidence of cardiovascular risks including any
of the following:

- QT interval corrected for heart rate using the Bazett's formula (QTcB) >= 480
msec. at baseline

- History of acute coronary syndromes (including myocardial infarction or unstable
angina), coronary angioplasty, or stenting within the past 24 weeks prior to
registration

- History prior to registration or evidence of current >= class II congestive heart
failure as defined by the New York Heart Association (NYHA) functional
classification system

- Left ventricular ejection fraction (LVEF) =< 45% on cardiac echocardiogram (echo)
or multi gated acquisition scan (MUGA)

- Intra-cardiac defibrillator

- Individuals who are known to be human immunodeficiency virus (HIV) infected are
eligible (note: HIV testing is not required for entry into the study)

- Patients with active autoimmune disease or history of autoimmune disease that might
recur, which may affect vital organ function or require immune suppressive treatment
including systemic corticosteroids, should be excluded; these include but are not
limited to patients with a history of immune related neurologic disease, multiple
sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia
gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE),
connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's,
ulcerative colitis, hepatitis; and patients with a history of toxic epidermal
necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be
excluded because of the risk of recurrence or exacerbation of disease; patients with
vitiligo, endocrine deficiencies including thyroiditis managed with replacement
hormones including physiologic corticosteroids are eligible; patients with rheumatoid
arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with
topical medication and patients with positive serology, such as antinuclear antibodies
(ANA), should be evaluated for the presence of target organ involvement and potential
need for systemic treatment; if no systemic immune suppression is deemed necessary
they can be eligible

- The following medications or non-drug therapies are also prohibited while on treatment
in this study:

- Other anti-cancer therapies

- Other investigational drugs

- Patients taking any medications or substances that are strong inhibitors or
inducers of CYP3A or CYP2C8 are ineligible

- Patients must not have history of retinal vein occlusion (RVO)

- Patients must not have evidence of interstitial lung disease or pneumonitis

- Patients must not have malabsorption, swallowing difficulty, or other conditions that
would interfere with the ingestion or absorption of dabrafenib or trametinib

- STEP 2 (CROSSOVER ARM FOR PATIENTS WITH PROGRESSIVE DISEASE)

- The patient must have met all eligibility criteria (except as detailed below) at the
time of crossover

- RECIST defined measurable disease is not required

- Only prior systemic therapy as part of step 1 is allowed; patients who received
allowed systemic therapy in the adjuvant setting prior to Step 1 and were
eligible for Step 1 are not excluded from proceeding to Step 2 if they meet other
eligibility criteria

- Malabsorption, swallowing difficulty, or other conditions that would interfere
with the ingestion or absorption of dabrafenib or trametinib, or history of
retinal vein occlusion are acceptable for patients crossing over to ipilimumab +
nivolumab treatment

- History of autoimmune disease, excluding interstitial lung disease or
pneumonitis, is allowed in patients crossing over to dabrafenib/trametinib
therapy

- Patients crossing over from nivolumab/ipilimumab to dabrafenib/trametinib who
underwent surgery or SRS to CNS metastases need not be off of steroids to start
treatment

- There is no restriction on serum lactate dehydrogenase (LDH) at crossover

- Patients with a history of cardiovascular risks that developed during step 1 of
therapy should be discussed with study principal investigator (PI) at time of
crossover

- Patients must have melanoma that is metastatic and clearly progressive on prior
therapy

- Patients must be at least 1 week from documented progressive disease (PD) on Step 1 of
current study; all sites of disease must be evaluated within 4 weeks prior to
registration

- Patients must have recovered from adverse events (toxicities resolved to grade 1 or
less) of prior therapy; patients with immune related toxicities from ipilimumab +
nivolumab may continue onto Step 2 even if still on steroids to control side effects,
so long as toxicity has resolved to grade 1 or less

- Patients must have discontinued radiation therapy prior to registering to Step 2 of
the study and recovered from any adverse events associated with treatment; prior
surgery must be >= 2 weeks from registration to Step 2 and patients must be fully
recovered from post-surgical complications

- Patients are ineligible if they have any currently active CNS metastases; patients who
have treated brain metastases (with either surgical resection or stereotactic
radiosurgery [SRS]) could be eligible to proceed; patients crossing over from
dabrafenib/trametinib to nivolumab (nivo)/ipilimumab (ipi) must not have taken any
steroids =< 10 days prior to registration for the purpose of managing their brain
metastases; patients with only whole brain irradiation for treatment of CNS metastases
are ineligible; patients with definitive CNS metastases treated with only WBRT are
ineligible; patients with potential CNS metastases that are too small for treatment
with either SRS or surgery (e.g. 1-2 mm) and/or are of uncertain etiology are
potentially eligible, but need to be discussed with and approved by the study PI

- Patients must not have other current malignancies

- Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab
or dabrafenib + trametinib on the developing human fetus are unknown; all females of
childbearing potential must have a blood test or urine study within 2 weeks prior to
registration to Step 2 crossover to rule out pregnancy; a female of childbearing
potential is any woman, regardless of sexual orientation or whether they have
undergone tubal ligation, who meets the following criteria: 1) has not undergone a
hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal
for at least 24 consecutive months (i.e., has had menses at any time in the preceding
24 consecutive months

- The effects of dabrafenib and trametinib or ipilimumab and nivolumab on the developing
human fetus are unknown; furthermore, dabrafenib has been reported to interfere with
the effect of hormone based oral contraceptives; for this reason and because other
therapeutic agents used in this trial are known to be teratogenic, women of
child-bearing potential and sexually active males must agree to continue to use the
same contraception requirements as on Step 1 of this study (i.e. use at least two
other accepted and effective methods of contraception and/or to abstain from sexual
intercourse for the duration of their participation in the study, and for at least 4
weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination
with trametinib; women of child-bearing potential must use at least two other accepted
and effective methods of contraception and/or to abstain from sexual intercourse for
at least 5

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A (immunotherapy)
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C.
  • Biological: Ipilimumab
    Given IV
    Other names:
    • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
    • BMS-734016
    • MDX-010
    • MDX-CTLA4
    • Yervoy
  • Biological: Nivolumab
    Given IV
    Other names:
    • BMS-936558
    • MDX-1106
    • NIVO
    • ONO-4538
    • Opdivo
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
Experimental
Arm B (BRAF inhibitor therapy)
Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.
  • Drug: Dabrafenib
    Given PO
    Other names:
    • BRAF Inhibitor GSK2118436
    • GSK-2118436
    • GSK-2118436A
    • GSK2118436
  • Drug: Dabrafenib Mesylate
    Given PO
    Other names:
    • Dabrafenib Methanesulfonate
    • GSK2118436 Methane Sulfonate Salt
    • GSK2118436B
    • Tafinlar
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Drug: Trametinib
    Given PO
    Other names:
    • GSK1120212
    • JTP-74057
    • MEK Inhibitor GSK1120212
    • Mekinist
  • Drug: Trametinib Dimethyl Sulfoxide
    Given PO
Experimental
Arm C (BRAF inhibitor therapy)
Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
  • Drug: Dabrafenib
    Given PO
    Other names:
    • BRAF Inhibitor GSK2118436
    • GSK-2118436
    • GSK-2118436A
    • GSK2118436
  • Drug: Dabrafenib Mesylate
    Given PO
    Other names:
    • Dabrafenib Methanesulfonate
    • GSK2118436 Methane Sulfonate Salt
    • GSK2118436B
    • Tafinlar
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Drug: Trametinib
    Given PO
    Other names:
    • GSK1120212
    • JTP-74057
    • MEK Inhibitor GSK1120212
    • Mekinist
  • Drug: Trametinib Dimethyl Sulfoxide
    Given PO
Experimental
Arm D (immunotherapy)
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
  • Biological: Ipilimumab
    Given IV
    Other names:
    • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
    • BMS-734016
    • MDX-010
    • MDX-CTLA4
    • Yervoy
  • Biological: Nivolumab
    Given IV
    Other names:
    • BMS-936558
    • MDX-1106
    • NIVO
    • ONO-4538
    • Opdivo
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment

Recruiting Locations

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
Contact:
Site Public Contact
205-934-0220
tmyrick@uab.edu

Anchorage Associates in Radiation Medicine
Anchorage, Alaska 98508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Anchorage Radiation Therapy Center
Anchorage, Alaska 99504
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Breast Care and Surgery LLC
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Oncology and Hematology LLC
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Women's Cancer Care
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Anchorage Oncology Centre
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Katmai Oncology Group
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Providence Alaska Medical Center
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Fairbanks Memorial Hospital
Fairbanks, Alaska 99701
Contact:
Site Public Contact
907-458-3043
cancerresearch@foundationhealth.org

Kingman Regional Medical Center
Kingman, Arizona 86401
Contact:
Site Public Contact
ecog.rss@jimmy.harvard.edu

CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas 71913
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Site Public Contact
501-686-8274

Kaiser Permanente-Anaheim
Anaheim, California 92806
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

PCR Oncology
Arroyo Grande, California 93420
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Sutter Auburn Faith Hospital
Auburn, California 95602
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California 95603
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Baldwin Park
Baldwin Park, California 91706
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Bellflower
Bellflower, California 90706
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California 94704
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California 91505
Contact:
Site Public Contact
818-847-4793
Najee.Boucher@providence.org

Mills-Peninsula Medical Center
Burlingame, California 94010
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California 95682
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Eden Hospital Medical Center
Castro Valley, California 94546
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Sutter Davis Hospital
Davis, California 95616
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

City of Hope Comprehensive Cancer Center
Duarte, California 91010
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente-Fontana
Fontana, California 92335
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Palo Alto Medical Foundation-Fremont
Fremont, California 94538
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Fresno
Fresno, California 93720
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente - Harbor City
Harbor City, California 90710
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Irvine
Irvine, California 92618
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente Los Angeles Medical Center
Los Angeles, California 90027
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Cadillac
Los Angeles, California 90034
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California 90095
Contact:
Site Public Contact
888-798-0719

Memorial Medical Center
Modesto, California 95355
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Modesto
Modesto, California 95356
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Palo Alto Medical Foundation-Camino Division
Mountain View, California 94040
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California 94040
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Oakland
Oakland, California 94611
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Ontario
Ontario, California 91761
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Palo Alto Medical Foundation Health Care
Palo Alto, California 94301
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente - Panorama City
Panorama City, California 91402
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Eisenhower Medical Center
Rancho Mirage, California 92270
Contact:
Site Public Contact
760-834-3798

Kaiser Permanente-Richmond
Richmond, California 94801
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Riverside
Riverside, California 92505
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Roseville
Roseville, California 95661
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California 95661
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Sutter Roseville Medical Center
Roseville, California 95661
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente Downtown Commons
Sacramento, California 95814
Contact:
Site Public Contact
877-642-4691
kpoct@kp.org

Sutter Medical Center Sacramento
Sacramento, California 95816
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente - Sacramento
Sacramento, California 95825
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-San Diego Mission
San Diego, California 92108
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-San Diego Zion
San Diego, California 92120
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

California Pacific Medical Center-Pacific Campus
San Francisco, California 94115
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Santa Teresa-San Jose
San Jose, California 95119
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente San Leandro
San Leandro, California 94577
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-San Marcos
San Marcos, California 92078
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-San Rafael
San Rafael, California 94903
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser San Rafael-Gallinas
San Rafael, California 94903
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California 95051
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California 95065
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Sutter Pacific Medical Foundation
Santa Rosa, California 95403
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Stockton
Stockton, California 95210
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California 94086
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

City of Hope Upland
Upland, California 91786
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California 95687
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Vallejo
Vallejo, California 94589
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Sutter Solano Medical Center/Cancer Center
Vallejo, California 94589
Contact:
Site Public Contact
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Walnut Creek
Walnut Creek, California 94596
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Woodland Hills
Woodland Hills, California 91367
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

University of Colorado Hospital
Aurora, Colorado 80045
Contact:
Site Public Contact
720-848-0650

Penrose-Saint Francis Healthcare
Colorado Springs, Colorado 80907
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado 80907
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Porter Adventist Hospital
Denver, Colorado 80210
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

SCL Health Saint Joseph Hospital
Denver, Colorado 80218
Contact:
Site Public Contact
303-777-2663
ccrp@co-cancerresearch.org

Mercy Medical Center
Durango, Colorado 81301
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Southwest Oncology PC
Durango, Colorado 81301
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado 80113
Contact:
Site Public Contact
303-777-2663
WSCR@westernstatesncorp.org

Swedish Medical Center
Englewood, Colorado 80113
Contact:
Site Public Contact
303-777-2663
ccrp@co-cancerresearch.org

Poudre Valley Hospital
Fort Collins, Colorado 80524
Contact:
Site Public Contact
970-297-6150

Grand Valley Oncology
Grand Junction, Colorado 81505
Contact:
Site Public Contact
970-644-4460
gvoclinicaltrials@gjhosp.org

North Colorado Medical Center
Greeley, Colorado 80631
Contact:
Site Public Contact
303-777-2663
ccrp@co-cancerresearch.org

Saint Anthony Hospital
Lakewood, Colorado 80228
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Littleton Adventist Hospital
Littleton, Colorado 80122
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Longmont United Hospital
Longmont, Colorado 80501
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado 80501
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

McKee Medical Center
Loveland, Colorado 80539
Contact:
Site Public Contact
303-777-2663
ccrp@co-cancerresearch.org

Parker Adventist Hospital
Parker, Colorado 80138
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Saint Mary Corwin Medical Center
Pueblo, Colorado 81004
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut 06105
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut 06510
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale University
New Haven, Connecticut 06520
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut 06360
Contact:
Site Public Contact
860-886-8362

MedStar Georgetown University Hospital
Washington, District of Columbia 20007
Contact:
Site Public Contact
202-444-2223

MedStar Washington Hospital Center
Washington, District of Columbia 20010
Contact:
Site Public Contact
202-877-8839

University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida 33136
Contact:
Site Public Contact
305-243-2647

University Cancer and Blood Center LLC
Athens, Georgia 30607
Contact:
Site Public Contact
706-353-5006
research@universitycancer.com

Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Site Public Contact
404-778-1868

Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
Contact:
Site Public Contact
404-851-7115

Northside Hospital
Atlanta, Georgia 30342
Contact:
Site Public Contact
404-303-3355
ClinicalTrials@northside.com

Augusta University Medical Center
Augusta, Georgia 30912
Contact:
Site Public Contact
706-721-2388
ga_cares@augusta.edu

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia 31405
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Summit Cancer Care-Candler
Savannah, Georgia 31405
Contact:
Site Public Contact
ecog.rss@jimmy.harvard.edu

Hawaii Cancer Care - Savio
'Aiea, Hawaii 96701
Contact:
Site Public Contact
808-539-2273

Hawaii Oncology Inc-Pali Momi
'Aiea, Hawaii 96701
Contact:
Site Public Contact
808-487-7447

Pali Momi Medical Center
'Aiea, Hawaii 96701
Contact:
Site Public Contact
808-486-6000

The Cancer Center of Hawaii-Pali Momi
'Aiea, Hawaii 96701
Contact:
Site Public Contact
808-678-9000

Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-524-6115

Hawaii Oncology Inc-POB I
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-532-0315

Island Urology
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-536-2306
virginia@cc.hawaii.edu

Queen's Medical Center
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-545-8548

Straub Clinic and Hospital
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-522-4333

University of Hawaii Cancer Center
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-586-2979

Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii 96817
Contact:
Site Public Contact
808-536-4888

Hawaii Oncology Inc-Kuakini
Honolulu, Hawaii 96817
Contact:
Site Public Contact
808-531-8521

Kuakini Medical Center
Honolulu, Hawaii 96817
Contact:
Site Public Contact
808-547-9816

The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii 96817
Contact:
Site Public Contact
808-547-6881

Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii 96819
Contact:
Site Public Contact
808-432-5195
shelley.a.clark@kp.org

Kapiolani Medical Center for Women and Children
Honolulu, Hawaii 96826
Contact:
Site Public Contact
808-983-6090

Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii 96766
Contact:
Site Public Contact
808-535-7960

Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho 83706
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Luke's Mountain States Tumor Institute
Boise, Idaho 83712
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho 83605
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Kootenai Medical Center
Coeur d'Alene, Idaho 83814
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Walter Knox Memorial Hospital
Emmett, Idaho 83617
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho 83619
Contact:
Site Public Contact
208-381-8059
hallsc@slhs.org

Idaho Urologic Institute-Meridian
Meridian, Idaho 83642
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho 83642
Contact:
Site Public Contact
208-381-8059
hallsc@slhs.org

Saint Alphonsus Medical Center-Nampa
Nampa, Idaho 83686
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho 83686
Contact:
Site Public Contact
208-381-8059
hallsc@slhs.org

Kootenai Cancer Center
Post Falls, Idaho 83854
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kootenai Cancer Clinic
Sandpoint, Idaho 83864
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Luke's Mountain States Tumor Institute-Twin Falls
Twin Falls, Idaho 83301
Contact:
Site Public Contact
208-381-8059
hallsc@slhs.org

Rush - Copley Medical Center
Aurora, Illinois 60504
Contact:
Site Public Contact
630-978-6212
Cancer.Research@rushcopley.com

Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Canton
Canton, Illinois 61520
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Memorial Hospital of Carbondale
Carbondale, Illinois 62902
Contact:
Site Public Contact
618-457-5200
clinical.research@sih.net

SIH Cancer Institute
Carterville, Illinois 62918
Contact:
Site Public Contact
618-985-3333
clinical.research@sih.net

Illinois CancerCare-Carthage
Carthage, Illinois 62321
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Centralia Oncology Clinic
Centralia, Illinois 62801
Contact:
Site Public Contact
217-876-4740
rhamrick@dmhhs.org

Northwestern University
Chicago, Illinois 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

Rush University Medical Center
Chicago, Illinois 60612
Contact:
Site Public Contact
312-942-5498
clinical_trials@rush.edu

Carle on Vermilion
Danville, Illinois 61832
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4740
rhamrick@dmhhs.org

Decatur Memorial Hospital
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4740
rhamrick@dmhhs.org

Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois 60115
Contact:
Site Public Contact
630-315-1918
claudine.gamster@nm.org

Illinois CancerCare-Dixon
Dixon, Illinois 61021
Contact:
Site Public Contact
815-285-7800

Carle Physician Group-Effingham
Effingham, Illinois 62401
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Crossroads Cancer Center
Effingham, Illinois 62401
Contact:
Site Public Contact
217-876-4740
rhamrick@dmhhs.org

Illinois CancerCare-Eureka
Eureka, Illinois 61530
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois 60201
Contact:
Site Public Contact
847-570-2109

Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Western Illinois Cancer Treatment Center
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-344-2831

Northwestern Medicine Cancer Center Delnor
Geneva, Illinois 60134
Contact:
Site Public Contact
630-315-1918
Claudine.Gamster@CadenceHealth.org

NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois 60026
Contact:
Site Public Contact
847-570-2109

NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois 60035
Contact:
Site Public Contact
847-570-2109

Joliet Oncology-Hematology Associates Limited
Joliet, Illinois 60435
Contact:
Site Public Contact
815-730-3098
maureenc@jolietoncology.com

Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

Illinois CancerCare-Macomb
Macomb, Illinois 61455
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Loyola University Medical Center
Maywood, Illinois 60153
Contact:
Site Public Contact
708-226-4357

Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Pekin
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peoria
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Methodist Medical Center of Illinois
Peoria, Illinois 61636
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Medical Center
Peoria, Illinois 61637
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peru
Peru, Illinois 61354
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Valley Radiation Oncology
Peru, Illinois 61354
Contact:
Site Public Contact
815-664-4141

Illinois CancerCare-Princeton
Princeton, Illinois 61356
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Southern Illinois University School of Medicine
Springfield, Illinois 62702
Contact:
Site Public Contact
217-545-7929

Springfield Clinic
Springfield, Illinois 62702
Contact:
Site Public Contact
800-444-7541

Memorial Medical Center
Springfield, Illinois 62781
Contact:
Site Public Contact
217-788-3528

Cancer Care Specialists of Illinois-Swansea
Swansea, Illinois 62226
Contact:
Site Public Contact
217-876-4740
rhamrick@dmhhs.org

Southwest Illinois Health Services LLP
Swansea, Illinois 62226
Contact:
Site Public Contact
618-236-1000
lynns@thecancercenter.com

Carle Cancer Center
Urbana, Illinois 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

The Carle Foundation Hospital
Urbana, Illinois 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois 60555
Contact:
Site Public Contact
630-315-1918
Claudine.Gamster@CadenceHealth.org

Rush-Copley Healthcare Center
Yorkville, Illinois 60560
Contact:
Site Public Contact
630-978-6212
Cancer.Research@rushcopley.com

Deaconess Clinic Downtown
Evansville, Indiana 47713
Contact:
Site Public Contact
877-654-0311
Research@Deaconess.com

Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana 46202
Contact:
Site Public Contact
317-278-5632
iutrials@iu.edu

Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana 46202
Contact:
Site Public Contact
317-278-5632
iutrials@iu.edu

Franciscan Health Indianapolis
Indianapolis, Indiana 46237
Contact:
Site Public Contact
317-528-7060

Springmill Medical Center
Indianapolis, Indiana 46290
Contact:
Site Public Contact
317-278-5632
iutrials@iu.edu

Woodland Cancer Care Center
Michigan City, Indiana 46360
Contact:
Site Public Contact
219-861-5800
sally.arnett@franciscanalliance.org

Franciscan Health Mooresville
Mooresville, Indiana 46158
Contact:
Site Public Contact
317-834-3603

Chancellor Center for Oncology
Newburgh, Indiana 47630
Contact:
Site Public Contact
877-654-0311
Research@Deaconess.com

Mary Greeley Medical Center
Ames, Iowa 50010
Contact:
Site Public Contact
515-956-4132

McFarland Clinic PC - Ames
Ames, Iowa 50010
Contact:
Site Public Contact
515-239-4734
ksoder@mcfarlandclinic.com

McFarland Clinic PC-Boone
Boone, Iowa 50036
Contact:
Site Public Contact
515-956-4132

Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa 50325
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Mercy Cancer Center-West Lakes
Clive, Iowa 50325
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Alegent Health Mercy Hospital
Council Bluffs, Iowa 51503
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa 50314
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa 50501
Contact:
Site Public Contact
515-956-4132

McFarland Clinic PC-Jefferson
Jefferson, Iowa 50129
Contact:
Site Public Contact
515-956-4132

McFarland Clinic PC-Marshalltown
Marshalltown, Iowa 50158
Contact:
Site Public Contact
515-956-4132

Siouxland Regional Cancer Center
Sioux City, Iowa 51101
Contact:
Site Public Contact
712-252-9326
HoopingarnerT@jencc.com

Mercy Medical Center-West Lakes
West Des Moines, Iowa 50266
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Cancer Center of Kansas - Chanute
Chanute, Kansas 66720
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Coffeyville Regional Medical Center
Coffeyville, Kansas 67337
Contact:
Site Public Contact
620-252-1606

Cancer Center of Kansas - Dodge City
Dodge City, Kansas 67801
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Cancer Center of Kansas - El Dorado
El Dorado, Kansas 67042
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Hays Medical Center
Hays, Kansas 67601
Contact:
Site Public Contact
785-623-5774

Cancer Center of Kansas-Independence
Independence, Kansas 67301
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

University of Kansas Cancer Center-West
Kansas City, Kansas 66112
Contact:
Site Public Contact
913-945-7552
ctnursenav@kumc.edu

University of Kansas Cancer Center
Kansas City, Kansas 66160
Contact:
Site Public Contact
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas-Kingman
Kingman, Kansas 67068
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Lawrence Memorial Hospital
Lawrence, Kansas 66044
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Cancer Center of Kansas-Liberal
Liberal, Kansas 67905
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Cancer Center of Kansas-Manhattan
Manhattan, Kansas 66502
Contact:
Site Public Contact
316-268-5784
Keisha.humphries@ascension.org

Cancer Center of Kansas - McPherson
McPherson, Kansas 67460
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Cancer Center of Kansas - Newton
Newton, Kansas 67114
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Olathe Medical Center
Olathe, Kansas 66061
Contact:
Site Public Contact
913-791-3500
Jeni.wakefield@olathehealth.org

University of Kansas Cancer Center-Overland Park
Overland Park, Kansas 66210
Contact:
Site Public Contact
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas - Parsons
Parsons, Kansas 67357
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Via Christi Hospital-Pittsburg
Pittsburg, Kansas 66762
Contact:
Site Public Contact
620-235-7900

Cancer Center of Kansas - Pratt
Pratt, Kansas 67124
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Cancer Center of Kansas - Salina
Salina, Kansas 67401
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Salina Regional Health Center
Salina, Kansas 67401
Contact:
Site Public Contact
785-452-7038
kkavoura@srhc.com

Saint Francis Hospital and Medical Center - Topeka
Topeka, Kansas 66606
Contact:
Site Public Contact
785-295-8000

Cancer Center of Kansas - Wellington
Wellington, Kansas 67152
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
Contact:
Site Public Contact
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas 67208
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Ascension Via Christi Hospitals Wichita
Wichita, Kansas 67214
Contact:
Site Public Contact
800-362-0070
Keisha.humphries@ascension.org

Cancer Center of Kansas - Wichita
Wichita, Kansas 67214
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Cancer Center of Kansas - Winfield
Winfield, Kansas 67156
Contact:
Site Public Contact
316-268-5374
Keisha.humphries@ascension.org

Flaget Memorial Hospital
Bardstown, Kentucky 40004
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Commonwealth Cancer Center-Corbin
Corbin, Kentucky 40701
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky 40504
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Saint Joseph Hospital East
Lexington, Kentucky 40509
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Saint Joseph London
London, Kentucky 40741
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Jewish Hospital
Louisville, Kentucky 40202
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky 40202
Contact:
Site Public Contact
502-562-3429

Saints Mary and Elizabeth Hospital
Louisville, Kentucky 40215
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Jewish Hospital Medical Center Northeast
Louisville, Kentucky 40245
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Jewish Hospital Medical Center South
Shepherdsville, Kentucky 40165
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana 70805
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana 70809
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana 70809
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Ochsner Health Center-Summa
Baton Rouge, Louisiana 70809
Contact:
Site Public Contact
225-761-5346
Camille.Beck@Ochsner.org

Our Lady of the Lake Physicians Group - Medical Oncology
Baton Rouge, Louisiana 70809
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Medical Center of Baton Rouge
Baton Rouge, Louisiana 70816
Contact:
Site Public Contact
225-761-5346
Camille.Beck@Ochsner.org

Ochsner High Grove
Baton Rouge, Louisiana 70836
Contact:
Site Public Contact
504-703-8712
Gregory.Johnstone@ochsner.org

Northshore Oncology Associates-Covington
Covington, Louisiana 70433
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Ochsner Medical Center Kenner
Kenner, Louisiana 70065
Contact:
Site Public Contact
504-464-8314
cris.molina@ochsner.org

Ochsner Medical Center Jefferson
New Orleans, Louisiana 70121
Contact:
Site Public Contact
504-703-8712
Gregory.Johnstone@ochsner.org

Greater Baltimore Medical Center
Baltimore, Maryland 21204
Contact:
Site Public Contact
443-849-3706

Saint Agnes Hospital
Baltimore, Maryland 21229
Contact:
Site Public Contact
410-368-2910

MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Baltimore, Maryland 21237
Contact:
Site Public Contact
443-777-7364

Frederick Memorial Hospital
Frederick, Maryland 21701
Contact:
Site Public Contact
240-566-3584
clinicaltrials@fmh.org

FMH James M Stockman Cancer Institute
Frederick, Maryland 21702
Contact:
Site Public Contact
301-668-7043

Mercy Medical Center
Springfield, Massachusetts 01104
Contact:
Site Public Contact
413-748-9234

Baystate Medical Center
Springfield, Massachusetts 01199
Contact:
Site Public Contact
413-794-3565
tamara.wrenn@baystatehealth.org

Hickman Cancer Center
Adrian, Michigan 49221
Contact:
Site Public Contact
517-265-0116

Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Bronson Battle Creek
Battle Creek, Michigan 49017
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Joseph Mercy Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

IHA Hematology Oncology Consultants-Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Joseph Mercy Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Caro Cancer Center
Caro, Michigan 48723
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Hematology Oncology Consultants-Clarkston
Clarkston, Michigan 48346
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Newland Medical Associates-Clarkston
Clarkston, Michigan 48346
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Ascension Saint John Hospital
Detroit, Michigan 48236
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan 48054
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Green Bay Oncology - Escanaba
Escanaba, Michigan 49829
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

Weisberg Cancer Treatment Center
Farmington Hills, Michigan 48334
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan 48503
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Genesee Hematology Oncology PC
Flint, Michigan 48503
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Genesys Hurley Cancer Institute
Flint, Michigan 48503
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Hurley Medical Center
Flint, Michigan 48503
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Mercy Health Saint Mary's
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Spectrum Health at Butterworth Campus
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan 48236
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan 48236
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan 48236
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Bronson Methodist Hospital
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Borgess Medical Center
Kalamazoo, Michigan 49048
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Sparrow Hospital
Lansing, Michigan 48912
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Hope Cancer Clinic
Livonia, Michigan 48154
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Mary Mercy Hospital
Livonia, Michigan 48154
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan 48044
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Michigan Breast Specialists-Macomb Township
Macomb, Michigan 48044
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Mary's Oncology/Hematology Associates of Marlette
Marlette, Michigan 48453
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Toledo Clinic Cancer Centers-Monroe
Monroe, Michigan 48162
Contact:
Site Public Contact
800-444-3561

Mercy Health Mercy Campus
Muskegon, Michigan 49444
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores, Michigan 49444
Contact:
Site Public Contact
616-391-1230
connie.szczepanek@crcwm.org

21st Century Oncology-Pontiac
Pontiac, Michigan 48341
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Hope Cancer Center
Pontiac, Michigan 48341
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Newland Medical Associates-Pontiac
Pontiac, Michigan 48341
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Joseph Mercy Oakland
Pontiac, Michigan 48341
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Spectrum Health Reed City Hospital
Reed City, Michigan 49677
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Great Lakes Cancer Management Specialists-Rochester Hills
Rochester Hills, Michigan 48309
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Ascension Saint Mary's Hospital
Saginaw, Michigan 48601
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan 48604
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, Michigan 48312
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Ascension Saint Joseph Hospital
Tawas City, Michigan 48764
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Advanced Breast Care Center PLLC
Warren, Michigan 48088
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, Michigan 48093
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Macomb Hematology Oncology PC
Warren, Michigan 48093
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Michigan Breast Specialists-Warren
Warren, Michigan 48093
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint John Macomb-Oakland Hospital
Warren, Michigan 48093
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Mary's Oncology/Hematology Associates of West Branch
West Branch, Michigan 48661
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Metro Health Hospital
Wyoming, Michigan 49519
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Huron Gastroenterology PC
Ypsilanti, Michigan 48106
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

IHA Hematology Oncology Consultants-Ann Arbor
Ypsilanti, Michigan 48197
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Sanford Joe Lueken Cancer Center
Bemidji, Minnesota 56601
Contact:
Site Public Contact
218-333-5000
OncologyClinicalTrialsFargo@sanfordhealth.org

Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota 56401
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Mercy Hospital
Coon Rapids, Minnesota 55433
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health - Deer River Clinic
Deer River, Minnesota 56636
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Saint Mary's - Detroit Lakes Clinic
Detroit Lakes, Minnesota 56501
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Cancer Center
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Saint Mary's Medical Center
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Miller-Dwan Hospital
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Fairview-Southdale Hospital
Edina, Minnesota 55435
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Lake Region Healthcare Corporation-Cancer Care
Fergus Falls, Minnesota 56537
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health - Fosston
Fosston, Minnesota 56542
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Unity Hospital
Fridley, Minnesota 55432
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Hibbing Clinic
Hibbing, Minnesota 55746
Contact:
Site Public Contact
218-786-3308

Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota 55109
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Abbott-Northwestern Hospital
Minneapolis, Minnesota 55407
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Hennepin County Medical Center
Minneapolis, Minnesota 55415
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Health Partners Inc
Minneapolis, Minnesota 55454
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health - Park Rapids
Park Rapids, Minnesota 56470
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

North Memorial Medical Health Center
Robbinsdale, Minnesota 55422
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Regions Hospital
Saint Paul, Minnesota 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

United Hospital
Saint Paul, Minnesota 55102
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Sandstone
Sandstone, Minnesota 55072
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Saint Francis Regional Medical Center
Shakopee, Minnesota 55379
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Lakeview Hospital
Stillwater, Minnesota 55082
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Sanford Thief River Falls Medical Center
Thief River Falls, Minnesota 56701
Contact:
Site Public Contact
605-312-3320

Essentia Health Virginia Clinic
Virginia, Minnesota 55792
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota 55125
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Sanford Cancer Center Worthington
Worthington, Minnesota 56187
Contact:
Site Public Contact
605-312-3320

Singing River Hospital
Pascagoula, Mississippi 39581
Contact:
Site Public Contact
228-809-5292

Parkland Health Center-Bonne Terre
Bonne Terre, Missouri 63628
Contact:
Site Public Contact
314-996-5569

Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

Southeast Cancer Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-651-5550

Parkland Health Center - Farmington
Farmington, Missouri 63640
Contact:
Site Public Contact
314-996-5569

Capital Region Southwest Campus
Jefferson City, Missouri 65109
Contact:
Site Public Contact
573-632-4814
swooden@mail.crmc.org

Truman Medical Center
Kansas City, Missouri 64108
Contact:
Site Public Contact
816-404-4375

Kansas City Veterans Affairs Medical Center
Kansas City, Missouri 64128
Contact:
Site Public Contact
800-525-1483

The University of Kansas Cancer Center-North
Kansas City, Missouri 64154
Contact:
Site Public Contact
913-945-7552
ctnursenav@kumc.edu

The University of Kansas Cancer Center-Lee's Summit
Lee's Summit, Missouri 64064
Contact:
Site Public Contact
913-945-7552
ctnursenav@kumc.edu

Missouri Baptist Medical Center
Saint Louis, Missouri 63131
Contact:
Site Public Contact
314-996-5569

Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
Contact:
Site Public Contact
314-996-5569

Mercy Hospital Springfield
Springfield, Missouri 65804
Contact:
Site Public Contact
417-269-4520

CoxHealth South Hospital
Springfield, Missouri 65807
Contact:
Site Public Contact
417-269-4520

Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
Contact:
Site Public Contact
314-996-5569

Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri 63127
Contact:
Site Public Contact
314-996-5569

Community Hospital of Anaconda
Anaconda, Montana 59711
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Bozeman Deaconess Hospital
Bozeman, Montana 59715
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint James Community Hospital and Cancer Treatment Center
Butte, Montana 59701
Contact:
Site Public Contact
406-723-2621

Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kalispell Regional Medical Center
Kalispell, Montana 59901
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Patrick Hospital - Community Hospital
Missoula, Montana 59802
Contact:
Site Public Contact
406-327-3118
amy.hanneman@providence.org

Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

CHI Health Saint Francis
Grand Island, Nebraska 68803
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

CHI Health Good Samaritan
Kearney, Nebraska 68847
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Saint Elizabeth Regional Medical Center
Lincoln, Nebraska 68510
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Nebraska Methodist Hospital
Omaha, Nebraska 68114
Contact:
Site Public Contact
402-354-5144

Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
Contact:
Site Public Contact
402-559-5600

Alegent Health Immanuel Medical Center
Omaha, Nebraska 68122
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska 68124
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Alegent Health Lakeside Hospital
Omaha, Nebraska 68130
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Creighton University Medical Center
Omaha, Nebraska 68131
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

University of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Midlands Community Hospital
Papillion, Nebraska 68046
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Carson Tahoe Regional Medical Center
Carson City, Nevada 89703
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Cancer and Blood Specialists-Henderson
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Cancer Center-Henderson
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Seven Hills
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

21st Century Oncology-Henderson
Henderson, Nevada 89074
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada 89074
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Urology - Green Valley
Henderson, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Pebble
Henderson, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Urology Specialists of Nevada - Green Valley
Henderson, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Pecos
Las Vegas, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Desert West Surgery
Las Vegas, Nevada 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

University Medical Center of Southern Nevada
Las Vegas, Nevada 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Hope Cancer Care of Nevada
Las Vegas, Nevada 89103
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Cancer and Blood Specialists-Shadow
Las Vegas, Nevada 89106
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Oakey
Las Vegas, Nevada 89106
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada 89106
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Urology Specialists of Nevada - Central
Las Vegas, Nevada 89106
Contact:
Site Public Contact
research@sncrf.org

21st Century Oncology
Las Vegas, Nevada 89109
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada 89109
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Sunrise Hospital and Medical Center
Las Vegas, Nevada 89109
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada 89113
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Prostate Cancer Center
Las Vegas, Nevada 89113
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Sunset
Las Vegas, Nevada 89113
Contact:
Site Public Contact
research@sncrf.org

Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada 89119
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Ann M Wierman MD LTD
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Urology - Cathedral Rock
Las Vegas, Nevada 89128
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Smoke Ranch
Las Vegas, Nevada 89128
Contact:
Site Public Contact
research@smcrf.org

OptumCare Cancer Care at MountainView
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Urology Specialists of Nevada - Northwest
Las Vegas, Nevada 89128
Contact:
Site Public Contact
research@sncrf.org

Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada 89135
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada 89144
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada 89144
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Summerlin Hospital Medical Center
Las Vegas, Nevada 89144
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada 89148-2405
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

21st Century Oncology-Fort Apache
Las Vegas, Nevada 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Urology Specialists of Nevada - Southwest
Las Vegas, Nevada 89148
Contact:
Site Public Contact
research@sncrf.org

HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada 89149
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada 89169
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

University Cancer Center
Las Vegas, Nevada 89169
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Hope Cancer Care of Nevada-Pahrump
Pahrump, Nevada 89048
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Renown Regional Medical Center
Reno, Nevada 89502
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Saint Mary's Regional Medical Center
Reno, Nevada 89503
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Radiation Oncology Associates
Reno, Nevada 89509
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Hackensack University Medical Center
Hackensack, New Jersey 07601
Contact:
Site Public Contact
201-996-2879

Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico 87102
Contact:
Site Public Contact
505-272-0530
AYost@nmcca.org

University of New Mexico Cancer Center
Albuquerque, New Mexico 87102
Contact:
Site Public Contact
505-925-0366
LByatt@nmcca.org

New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico 87109
Contact:
Site Public Contact
505-272-0530
CLee@nmcca.org

Memorial Medical Center - Las Cruces
Las Cruces, New Mexico 88011
Contact:
Site Public Contact
575-556-6545
Kim.Hoffman@lpnt.net

Presbyterian Rust Medical Center/Jorgensen Cancer Center
Rio Rancho, New Mexico 87124
Contact:
Site Public Contact
505-559-6113
WBurman@phs.org

New York Oncology Hematology PC -Albany Medical Center
Albany, New York 12208
Contact:
Site Public Contact
518-489-3612
jennifer.moran@usoncology.com

Mary Imogene Bassett Hospital
Cooperstown, New York 13326
Contact:
Site Public Contact
877-547-1750
CancerClinicalTrials@bassett.org

Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina 28328
Contact:
Site Public Contact
919-587-9077
ecooke@cancersmoc.com

Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina 27534
Contact:
Site Public Contact
919-587-9077
ecooke@cancersmoc.com

Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina 28791
Contact:
Site Public Contact
828-696-4716
karen.morris@unchealth.unc.edu

Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina 28546
Contact:
Site Public Contact
910-353-0824
ecooke@cancersmoc.com

Wake Forest University Health Sciences
Winston-Salem, North Carolina 27157
Contact:
Site Public Contact
336-713-6771

Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Essentia Health Cancer Center-South University Clinic
Fargo, North Dakota 58103
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Sanford South University Medical Center
Fargo, North Dakota 58103
Contact:
Site Public Contact
701-234-6161

Sanford Broadway Medical Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Clinic North-Fargo
Fargo, North Dakota 58122
Contact:
Preston D. Steen
712-252-0088

Sanford Roger Maris Cancer Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

Essentia Health - Jamestown Clinic
Jamestown, North Dakota 58401
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio 44122
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Dayton Physicians LLC-Miami Valley South
Centerville, Ohio 45459
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Miami Valley Hospital South
Centerville, Ohio 45459
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio 45220
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Bethesda North Hospital
Cincinnati, Ohio 45242
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

TriHealth Cancer Institute-Westside
Cincinnati, Ohio 45247
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

TriHealth Cancer Institute-Anderson
Cincinnati, Ohio 45255
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Case Western Reserve University
Cleveland, Ohio 44106
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

MetroHealth Medical Center
Cleveland, Ohio 44109
Contact:
Site Public Contact
216-778-8526
dstrater@metrohealth.org

Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

Cleveland Clinic Foundation
Cleveland, Ohio 44195
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Contact:
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Columbus Oncology and Hematology Associates Inc
Columbus, Ohio 43214
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Riverside Methodist Hospital
Columbus, Ohio 43214
Contact:
Site Public Contact
614-566-4475
sheree@columbusccop.org

Grant Medical Center
Columbus, Ohio 43215
Contact:
Site Public Contact
614-566-4475
sheree@columbusccop.org

Good Samaritan Hospital - Dayton
Dayton, Ohio 45406
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Miami Valley Hospital
Dayton, Ohio 45409
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Dayton Physician LLC-Miami Valley Hospital North
Dayton, Ohio 45415
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Miami Valley Hospital North
Dayton, Ohio 45415
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Dayton Physicians LLC-Atrium
Franklin, Ohio 45005
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Dayton Physicians LLC-Wayne
Greenville, Ohio 45331
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Greater Dayton Cancer Center
Kettering, Ohio 45409
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Kettering Medical Center
Kettering, Ohio 45429
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Cleveland Clinic Cancer Center Mansfield
Mansfield, Ohio 44906
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio 44124
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

Licking Memorial Hospital
Newark, Ohio 43055
Contact:
Site Public Contact
740-348-4000
sheree@columbusccop.org

Newark Radiation Oncology
Newark, Ohio 43055
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Mercy Health Perrysburg Cancer Center
Perrysburg, Ohio 43551
Contact:
Site Public Contact
419-479-5605
pshoup@toledoclinic.com

Southern Ohio Medical Center
Portsmouth, Ohio 45662
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

North Coast Cancer Care
Sandusky, Ohio 44870
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

Mercy Saint Anne Hospital
Toledo, Ohio 43623
Contact:
Site Public Contact
419-407-1160

Toledo Clinic Cancer Centers-Toledo
Toledo, Ohio 43623
Contact:
Site Public Contact
800-444-3561

Dayton Physicians LLC-Upper Valley
Troy, Ohio 45373
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

Upper Valley Medical Center
Troy, Ohio 45373
Contact:
Site Public Contact
937-775-1350
som_dcop@wright.edu

South Pointe Hospital
Warrensville Heights, Ohio 44122
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

UHHS-Westlake Medical Center
Westlake, Ohio 44145
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Cleveland Clinic Wooster Family Health and Surgery Center
Wooster, Ohio 44691
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Integris Southwest Medical Center
Oklahoma City, Oklahoma 73109
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Saint Alphonsus Medical Center-Baker City
Baker City, Oregon 97814
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Charles Health System
Bend, Oregon 97701
Contact:
Site Public Contact
541-706-2909
nosall@stcharleshealthcare.org

Clackamas Radiation Oncology Center
Clackamas, Oregon 97015
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Oncology and Hematology Care Southeast
Clackamas, Oregon 97015
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Bay Area Hospital
Coos Bay, Oregon 97420
Contact:
Site Public Contact
541-269-8392
cherie.cox@bayareahospital.org

Providence Newberg Medical Center
Newberg, Oregon 97132
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Saint Alphonsus Medical Center-Ontario
Ontario, Oregon 97914
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Providence Portland Medical Center
Portland, Oregon 97213
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Portland, Oregon 97225
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Saint Charles Health System-Redmond
Redmond, Oregon 97756
Contact:
Site Public Contact
541-706-2909

Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania 18017
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Chambersburg Hospital
Chambersburg, Pennsylvania 17201
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Pocono Medical Center
East Stroudsburg, Pennsylvania 18301
Contact:
Site Public Contact
570-422-1700
ann.foster@lvhn.org

Ephrata Cancer Center
Ephrata, Pennsylvania 17522
Contact:
Site Public Contact
717-721-4840

Ephrata Community Hospital
Ephrata, Pennsylvania 17522
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Adams Cancer Center
Gettysburg, Pennsylvania 17325
Contact:
Site Public Contact
877-441-7957

Cherry Tree Cancer Center
Hanover, Pennsylvania 17331
Contact:
Site Public Contact
877-441-7957

Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania 18201
Contact:
Site Public Contact
570-459-2901
HemonCCTrials@geisinger.edu

Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania 18201
Contact:
Site Public Contact
570-501-1242

Sechler Family Cancer Center
Lebanon, Pennsylvania 17042
Contact:
Site Public Contact
717-741-8303
doxenberg@wellspan.org

Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania 17837
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

Lewistown Hospital
Lewistown, Pennsylvania 17044
Contact:
Site Public Contact
717-242-7703
HemonCCTrials@geisinger.edu

Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
Contact:
Site Public Contact
877-284-2000

West Penn Hospital
Pittsburgh, Pennsylvania 15224
Contact:
Site Public Contact
412-578-5000

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-647-8073

Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania 17901
Contact:
Site Public Contact
800-275-6401
HemonCCTrials@geisinger.edu

Guthrie Medical Group PC-Robert Packer Hospital
Sayre, Pennsylvania 18840
Contact:
Site Public Contact
800-836-0388

Community Medical Center
Scranton, Pennsylvania 18510
Contact:
Site Public Contact
570-703-4768
HemonCCTrials@geisinger.edu

Geisinger Medical Oncology-Selinsgrove
Selinsgrove, Pennsylvania 17870
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

Geisinger Medical Group
State College, Pennsylvania 16801
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Reading Hospital
West Reading, Pennsylvania 19611
Contact:
Site Public Contact
610-988-9323

Wexford Health and Wellness Pavilion
Wexford, Pennsylvania 15090
Contact:
Site Public Contact
412-359-3043
ddefazio@wpahs.org

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

WellSpan Health-York Cancer Center
York, Pennsylvania 17403
Contact:
Site Public Contact
877-441-7957

WellSpan Health-York Hospital
York, Pennsylvania 17403
Contact:
Site Public Contact
877-441-7957

Rhode Island Hospital
Providence, Rhode Island 02903
Contact:
Site Public Contact
401-444-1488

Medical University of South Carolina
Charleston, South Carolina 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Prisma Health Cancer Institute - Easley
Easley, South Carolina 29640
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Saint Francis Hospital
Greenville, South Carolina 29601
Contact:
Site Public Contact
864-603-6213
meissa_beckman@bshsi.org

Prisma Health Cancer Institute - Butternut
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Prisma Health Cancer Institute - Faris
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Prisma Health Greenville Memorial Hospital
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Saint Francis Cancer Center
Greenville, South Carolina 29607
Contact:
Site Public Contact
864-603-6213
meissa_beckman@bshsi.org

Prisma Health Cancer Institute - Eastside
Greenville, South Carolina 29615
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Prisma Health Cancer Institute - Greer
Greer, South Carolina 29650
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

The Radiation Oncology Center-Hilton Head/Bluffton
Hilton Head Island, South Carolina 29926
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Prisma Health Cancer Institute - Seneca
Seneca, South Carolina 29672
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Prisma Health Cancer Institute - Spartanburg
Spartanburg, South Carolina 29307
Contact:
Site Public Contact
864-522-2066
kim.williams3@prismahealth.org

Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Avera Cancer Institute
Sioux Falls, South Dakota 57105
Contact:
Site Public Contact
888-634-7268
oncregulatory@avera.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Erlanger Medical Center
Chattanooga, Tennessee 37403
Contact:
Site Public Contact
423-778-6947

Vanderbilt-Ingram Cancer Center Cool Springs
Franklin, Tennessee 37067
Contact:
Site Public Contact
800-811-8480

Regional Cancer Center at Indian Path Community Hospital
Kingsport, Tennessee 37660
Contact:
Site Public Contact
423-578-8538
Justin.reynolds@balladhealth.org

Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee 37660
Contact:
Site Public Contact
423-578-8538
justin.reynolds@wellmont.org

Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee 37204
Contact:
Site Public Contact
800-811-8480

Saint Joseph Regional Cancer Center
Bryan, Texas 77802
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah 84003
Contact:
Site Public Contact
801-855-4100
officeofresearch@imail.org

Sandra L Maxwell Cancer Center
Cedar City, Utah 84720
Contact:
Site Public Contact
435-868-5680
officeofresearch@imail.org

Logan Regional Hospital
Logan, Utah 84321
Contact:
Site Public Contact
435-716-6400
officeofresearch@imail.org

Intermountain Medical Center
Murray, Utah 84107
Contact:
Site Public Contact
801-507-3950
officeofresearch@imail.org

McKay-Dee Hospital Center
Ogden, Utah 84403
Contact:
Site Public Contact
801-387-7426
officeofresearch@imail.org

Utah Valley Regional Medical Center
Provo, Utah 84604
Contact:
Site Public Contact
801-357-7965
officeofresearch@imail.org

Riverton Hospital
Riverton, Utah 84065
Contact:
Site Public Contact
801-507-3950
officeofresearch@imail.org

Dixie Medical Center Regional Cancer Center
Saint George, Utah 84770
Contact:
Site Public Contact
435-688-4167
officeofresearch@imail.org

Utah Cancer Specialists-Salt Lake City
Salt Lake City, Utah 84106
Contact:
Site Public Contact
801-933-6070
officeofresearch@imail.org

LDS Hospital
Salt Lake City, Utah 84143
Contact:
Site Public Contact
801-408-1347
officeofresearch@imail.org

University of Virginia Cancer Center
Charlottesville, Virginia 22908
Contact:
Site Public Contact
434-243-6303
PAS9E@virginia.edu

Southwest VA Regional Cancer Center
Norton, Virginia 24273
Contact:
Site Public Contact
423-578-8538
justin.reynolds@wellmont.org

Providence Regional Cancer System-Aberdeen
Aberdeen, Washington 98520
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

MultiCare Auburn Medical Center
Auburn, Washington 98001
Contact:
Site Public Contact
253-887-9333
research@multicare.org

PeaceHealth Saint Joseph Medical Center
Bellingham, Washington 98225
Contact:
Site Public Contact
360-715-4133
mjohnson9@peacehealth.org

Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington 98310
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Harrison Medical Center
Bremerton, Washington 98310
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Highline Medical Center-Main Campus
Burien, Washington 98166
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Providence Regional Cancer System-Centralia
Centralia, Washington 98531
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

Swedish Cancer Institute-Edmonds
Edmonds, Washington 98026
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Saint Elizabeth Hospital
Enumclaw, Washington 98022
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Providence Regional Cancer Partnership
Everett, Washington 98201
Contact:
Site Public Contact
425-261-3529
marilyn.birchman@providence.org

Saint Francis Hospital
Federal Way, Washington 98003
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

MultiCare Gig Harbor Medical Park
Gig Harbor, Washington 98335
Contact:
Site Public Contact
253-403-2394
research@multicare.org

Swedish Cancer Institute-Issaquah
Issaquah, Washington 98029
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Kadlec Clinic Hematology and Oncology
Kennewick, Washington 99336
Contact:
Site Public Contact
509-783-4637
research@kadlecmed.org

Providence Regional Cancer System-Lacey
Lacey, Washington 98503
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

Saint Clare Hospital
Lakewood, Washington 98499
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

PeaceHealth Saint John Medical Center
Longview, Washington 98632
Contact:
Site Public Contact
360-514-2016
kmakin-bond@peacehealth.org

Jefferson Healthcare
Port Townsend, Washington 98368
Contact:
Site Public Contact
360-344-3091

Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington 98370
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

MultiCare Good Samaritan Hospital
Puyallup, Washington 98372
Contact:
Site Public Contact
800-351-7955
research@multicare.org

Pacific Gynecology Specialists
Seattle, Washington 98104
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Medical Center-Ballard Campus
Seattle, Washington 98107
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Medical Center-First Hill
Seattle, Washington 98122-4307
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Medical Center-Cherry Hill
Seattle, Washington 98122-5711
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

PeaceHealth United General Medical Center
Sedro-Woolley, Washington 98284
Contact:
Site Public Contact
360-788-8240

Providence Regional Cancer System-Shelton
Shelton, Washington 98584
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

Rockwood Clinic Cancer Treatment Center-Valley
Spokane Valley, Washington 99216
Contact:
Site Public Contact
509-724-4454
apope@rockwoodclinic.com

Rockwood Cancer Treatment Center-DHEC-Downtown
Spokane, Washington 99204
Contact:
Site Public Contact
509-724-4454
apope@rockwoodclinic.com

Rockwood North Cancer Treatment Center
Spokane, Washington 99218
Contact:
Site Public Contact
509-724-4454
apope@rockwoodclinic.com

Franciscan Research Center-Northwest Medical Plaza
Tacoma, Washington 98405
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Mary Bridge Children's Hospital and Health Center
Tacoma, Washington 98405
Contact:
Site Public Contact
253-403-1461
research@multicare.org

MultiCare Tacoma General Hospital
Tacoma, Washington 98405
Contact:
Site Public Contact
253-403-3229
research@multicare.org

PeaceHealth Southwest Medical Center
Vancouver, Washington 98664
Contact:
Site Public Contact
360-514-3940
kmakin-bond@peacehealth.org

Providence Saint Mary Regional Cancer Center
Walla Walla, Washington 99362
Contact:
Site Public Contact
509-897-5993
Cheryl.Dodd@providence.org

Providence Regional Cancer System-Yelm
Yelm, Washington 98597
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

United Hospital Center
Bridgeport, West Virginia 26330
Contact:
Site Public Contact
304-293-7374
cancertrialsinfo@hsc.wvu.edu

West Virginia University Charleston Division
Charleston, West Virginia 25304
Contact:
Site Public Contact
304-388-9944

WVUH-Berkely Medical Center
Martinsburg, West Virginia 25401
Contact:
Site Public Contact
304-293-7374
cancertrialsinfo@hsc.wvu.edu

West Virginia University Healthcare
Morgantown, West Virginia 26506
Contact:
Site Public Contact
304-293-7374
cancertrialsinfo@hsc.wvu.edu

Camden Clark Medical Center
Parkersburg, West Virginia 26101
Contact:
Site Public Contact
304-293-7374
cancertrialsinfo@hsc.wvu.edu

Langlade Hospital and Cancer Center
Antigo, Wisconsin 54409
Contact:
Site Public Contact
715-623-9869
Juli.Alford@aspirus.org

Duluth Clinic Ashland
Ashland, Wisconsin 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Northwest Wisconsin Cancer Center
Ashland, Wisconsin 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin 54729
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin 54701
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin 54301-3526
Contact:
Brian L. Burnette
920-433-8889

Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin 54301
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin 54303
Contact:
Brian L. Burnette
920-433-8889

Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin 54303
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin 53038
Contact:
Site Public Contact
920-699-3500
lynda.persico@uwmf.wisc.edu

Gundersen Lutheran Medical Center
La Crosse, Wisconsin 54601
Contact:
Site Public Contact
608-775-2385
cancerctr@gundersenhealth.org

Marshfield Clinic - Ladysmith Center
Ladysmith, Wisconsin 54848
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

University of Wisconsin Hospital and Clinics
Madison, Wisconsin 53792
Contact:
Site Public Contact
800-622-8922

Holy Family Memorial Hospital
Manitowoc, Wisconsin 54221
Contact:
Site Public Contact
920-320-2749

Saint Vincent Hospital Cancer Center at Marinette
Marinette, Wisconsin 54143
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Site Public Contact
414-805-3666

Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin 54548
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Cancer Center of Western Wisconsin
New Richmond, Wisconsin 54017
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Saint Vincent Hospital Cancer Center at Oconto Falls
Oconto Falls, Wisconsin 54154
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin 54868
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

HSHS Saint Nicholas Hospital
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

Marshfield Clinic Stevens Point Center
Stevens Point, Wisconsin 54482
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin 54235-1495
Contact:
Site Public Contact
920-433-8889
Christy.Gilchrist@hshs.org

Green Bay Oncology - Sturgeon Bay
Sturgeon Bay, Wisconsin 54235
Contact:
Brian L. Burnette
920-433-8889

Aspirus Regional Cancer Center
Wausau, Wisconsin 54401
Contact:
Site Public Contact
877-405-6866

Marshfield Clinic-Wausau Center
Wausau, Wisconsin 54401
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Marshfield Clinic - Weston Center
Weston, Wisconsin 54476
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aspirus UW Cancer Center
Wisconsin Rapids, Wisconsin 54494
Contact:
Site Public Contact
715-422-7718

Marshfield Clinic - Wisconsin Rapids Center
Wisconsin Rapids, Wisconsin 54494
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

More Details

NCT ID
NCT02224781
Status
Recruiting
Sponsor
National Cancer Institute (NCI)

Detailed Description

PRIMARY OBJECTIVE:

I. To determine whether initial treatment with either combination ipilimumab + nivolumab (with subsequent dabrafenib mesylate [dabrafenib] in combination with trametinib dimethyl sulfoxide [trametinib]) or dabrafenib in combination with trametinib (with subsequent ipilimumab + nivolumab) significantly improves 2 year overall survival (OS) in patients with unresectable stage III or stage IV BRAFV600 mutant melanoma.

SECONDARY CLINICAL OBJECTIVES:

I. To evaluate the impact of initial treatment on median OS and hazard ratio for death.

II. To determine whether initial treatment choice significantly improves 3 year OS.

III. To evaluate the anti-tumor activities (Response Evaluation Criteria in Solid Tumors [RECIST]-defined response rate, median progression-free survival [PFS]) and safety profiles of ipilimumab + nivolumab and dabrafenib-trametinib in a Cooperative Group trial of patients with V600 mutant melanoma.

IV. To evaluate the activity (RECIST-defined response rate, median PFS) and safety of dabrafenib + trametinib in patients who have had disease progression on ipilimumab + nivolumab and in comparison to its activity and safety in ipilimumab + nivolumab naive patients.

V. To evaluate the activity of ipilimumab + nivolumab (RECIST-defined response rate, median PFS) and safety in patients who have had disease progression on dabrafenib + trametinib and in comparison to its activity and safety in dabrafenib + trametinib naive patients.

VI. To assess the feasibility of crossover to the alternative treatment strategy (percentage of patients who are able to crossover from one arm to the other and complete at least an initial course [12 weeks] of treatment after cross-over without intervening symptomatic disease progression or treatment limiting toxicity).

SECONDARY LABORATORY OBJECTIVES:

I. Association of inherited variation with immune mediated adverse events and response to ipilimumab + nivolumab.

Ia. To determine the association of inherited genetic variation and immune-associated adverse events in patients with metastatic melanoma treated with ipilimumab containing regimens by completing candidate-based gene and pathway analyses of genes involved in lymphocyte activation, cytokines, cytokine receptors and within the major histocompatibility complex (MHC) region and an agnostic genome-wide single nucleotide polymorphism (SNP)-based approach.

Ib. To investigate the association between inherited genetics and survival in patients with metastatic melanoma treated with ipilimumab containing regimens by completing candidate-based gene and pathway analyses of genes involved in lymphocyte activation, cytokines profile, cytokine receptors and within the MHC region and an agnostic genome-wide SNP-based approach.

Ic. To replicate genomic markers identified in the above aims in an independent sample set of patients treated with ipilimumab containing regimens and preliminarily characterize their potential functional role by completing replication of variation as associated with immune-related adverse events (irAEs) and survival and bio-informatic assessment of genomic markers.

II. To determine the utility of circulating BRAF levels in determining the response and resistance to either BRAF/MEK directed and/or combination immunotherapy in patients with BRAF mutant melanoma.

IIa. To determine if changes in blood BRAF levels utilizing peripheral blood BRAFV600 mutational testing in patients with stage IV BRAF mutant melanoma correlate with response and resistance to combination BRAF/MEK directed therapy.

IIb. To determine if changes in blood BRAF levels utilizing peripheral blood BRAFV600 mutational testing in patients with stage IV BRAF mutant melanoma correlate with response and resistance to combination immunotherapy.

IIc. To compare the kinetics of peripheral blood BRAFV600 levels during response and resistance in groups of patients receiving BRAF targeted therapy or combination immunotherapy as initial therapy.

IId. To compare the kinetics of peripheral blood BRAFV600 levels during response and resistance to combination BRAF targeted therapy or combination immunotherapy in individual patients (initial treatment vs crossover treatment).

SECONDARY PATIENT REPORTED OUTCOMES OBJECTIVES:

I. To evaluate differences in overall health between initial treatment arms (dabrafenib + trametinib vs. ipilimumab + nivolumab immunotherapy) at 2 years, accounting for toxicities and overall survival. (Primary) II. To assess differences in overall function over 2 years between initial treatment with dabrafenib + trametinib vs. ipilimumab + nivolumab. (Secondary) III. To document the effects of treatment crossover and treatment administration sequence on symptom burden and overall function. (Secondary) IIIa. To compare differences in function and symptoms by treatment sequence for ipilimumab + nivolumab (arm A vs. D), and dabrafenib + trametinib, (arm B vs. C) at baseline, 6 weeks, 12 weeks, and 6 months after the initiation of each treatment.

IIIb. To describe the frequency and severity of treatment toxicities at baseline, 6 weeks, 12 weeks, and 6 months after initiation of each treatment.

EXPLORATORY TOBACCO USE OBJECTIVES:

I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events [both clinical and hematologic] and dose modifications).

II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.

III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.

IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.

OUTLINE: Patients are randomized to 1 of 2 treatment arms (Arm A or Arm B).

ARM A:

IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab intravenously (IV) over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.

IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C.

ARM C: Patients receive dabrafenib mesylate orally (PO) twice daily (BID) and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.

ARM D:

IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.

IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.